Castrators cut down Proteus results
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.PROTEUS, the USM-quoted biotechnology company, reported a pre-tax loss of pounds 2.73m for the six months to September, compared with an interim loss of pounds 1.21m the previous year, writes Diane Coyle.
The weaker result was due to the expansion of the company's product development programme last year. According to Kevin Gilmore, executive chairman, spending will now level off.
Proteus has two animal health products in preliminary veterinary trials. The first, a chemical castrator for cats, could reach the market soon, followed about a year later by the doggy version.
Proteus hopes to have 10 human and animal products in the first stage of clinical trials by the end of the year. Two more start next month. However, it will be at least five years before any of its products for humans have passed through all the regulatory hoops to reach the market.
The company has recently formed joint ventures with Medeva and American Home Products Corporation. These much bigger partners will take responsibility for the regulatory approval and marketing of Proteus discoveries - vaccines for hepatitis B and C in the former case, and animal health products in the latter. Mr Gilmore said: 'We will seek a whole range of joint venture partners.'
The share price closed 19p down at 423p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments